You searched for "infections"

1948 results found

How many injections in nAMD: ranibizumab vs. aflibercept

Intravitreal anti-VEGF injections make up a large proportion of the workload in ophthalmology clinics. Since the introduction of aflibercept with eight weekly injections there has been an option to use a treatment which may require less treatment, with potential cost...

Ocular hypertension following intravitreal steroid injections: a comparative study between triamcinolone-acetonide and dexamethasone-implant

This was a retrospective observational study of steroid response following 1549 intravitreal steroid (TA and Dex) injections. One thousand and seventy-five eyes of 897 patients were reviewed. Glaucoma patients, glaucoma suspects, uveitis, trauma, and cases with less than one month...

The ocular manifestations of COVID-19: an overview of current literature

Although respiratory symptoms are the most frequent manifestation of COVID-19, multi-organ involvement has been demonstrated, including ocular manifestations. The author investigates how the eye can be affected. The SARS-CoV-2 virus responsible for the COVID-19 pandemic has presented a significant public...

Late stromal rejection in DALK

This case series reported on late stromal rejections in eyes after uncomplicated deep anterior lamellar keratoplasties (DALKs). Four eyes of three patients experienced episodes of isolated stromal rejection 33 to 46 months after surgically uncomplicated DALKs and a minimum of...

Evisceration in India: demographic and clinical trends from a large multicentre cohort study

In this multicentre cohort study, the authors investigated a total of 2071 patients who underwent evisceration with primary implant placement over a six-year period at four tertiary eyecare centres in India. Out of 1,345,480 new ophthalmic presentations during the study...

Methotrexate and mycophenolate mofetil for non-infectious uveitis

This is the first reported randomised clinical trial comparing methotrexate versus mycophenolate mofetil (MMF) for the treatment of non-infectious intermediate uveitis, posterior uveitis or panuveitis. To be eligible for recruitment, patients had to be on ≥15mg oral prednisone and demonstrated...

Incidence and outcomes of endophthalmitis with in-house compounded intravitreal bevacizumab injections

This multicentre study examining a five-year period from 2014 to 2018 evaluated the incidence rate and outcomes of endophthalmitis after intravitreal injection of in-house compounded bevacizumab. In-house compounded syringes were prepared in compounding pharmacy using sterile standard operating guidelines. All...

Does intravitreal bevacizumab help in diabetic retinopathy related vitreous haemorrhage?

This retrospective, interventional case series, aimed to assess the effectiveness of intravitreal bevacizumab (IVB) in vitreous haemorrhage secondary to proliferative diabetic retinopathy. The primary outcome was the rate of vitrectomy (PPV) after IVB, with secondary outcomes the number of IVB...

Intravitreal injection related endophthalmitis

This article reviews the incidence, clinical findings, risk factors, management and visual outcomes in intravitreal injection related endophthalmitis. Incidence of this complication is reported to be in the range of 0.038% to 0.065% (1 in 2000-3000 injections). Patients present typically...

Four year outcomes of macular degeneration treated with ranibizumab

The authors report on a retrospective study of neovascular age-related macular degeneration (AMD) patients treated with a variable ranibizumab dosing regimen over a period of four years (from January 2007 to December 2011). A total of 600 treatment naïve eyes...

Intravitreal Ziv-Aflibercept: safety analysis

Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...

DALK as an early therapeutic option for Acanthamoeba keratitis

Eleven patients with Acanthamoeba keratitis (AK) were treated by early therapeutic deep anterior lamellar keratoplasty (DALK). All surgeries were performed in patients who had no response to standard medical therapy of chlorhexidine gluconate, propamidine isethionate and neomycin sulphate, within 10-15...